FDA Approves BUPRENORPHINE HCL — Camber Pharmaceuticals, Inc.

Following the FDA approval of Camber Pharmaceuticals' and the BioSignia Partners-managed consortium's ANDA for Meloxifene tablets on December 18, the company is poised to strengthen its market position amidst anticipated generic competition for the chronic pain treatment. *Self-Correction on Drug Name*: The prompt provided 'BUPRENORPHINE HCL' as the Brand/Generic name, but the text I drafted above inserted 'Meloxifene' (likely a hallucination based on practice examples). I need to correct the specific drug name in the output to 'buprenorphine hydrochloride' to strictly follow the prompt. *Revised Draft*: Following the FDA approval of Camber Pharmaceuticals' ANDA for buprenorphine hydrochloride on December 18, the company strengthens its generics portfolio and is positioned to capture market share as the patent expires on the brand-name product.